[ 메디채널 김갑성 기자 ] Joint effort to explore innovative cancer treatment solutions and broaden options for customers HONG KONG, July 15, 2025 -- AXA China Region Insurance Company (Bermuda) Limited, together with AXA International Reinsurance (Shanghai) Company Limited ("AXA"), is pleased to announce the signing of a strategic Memorandum of Understanding (MoU) with China Biotech Services Holdings Limited ("China Biotech Services"). The collaboration aims to explore innovative cancer treatment technologies, including Boron Neutron Capture Therapy ("BNCT") and
TVM Capital Healthcare's oversubscribed fundraise for Baraya Extended Care addresses critical gaps in long-term care, supporting Saudi Arabia's Vision 2030 healthcare goals. DUBAI, UAE and RIYADH, Saudi Arabia, July 15, 2025 -- TVM Capital Healthcare announces the closing of a Series B fundraising, surpassing its target and bringing the total capital raised to USD 124 million for Baraya Extended Care ["Baraya"], a leading provider of long-term care and rehabilitation services in Saudi Arabia. This fundraise comes at a critical moment, as Saudi Arabia faces a
TVM Capital Healthcare's oversubscribed fundraise for Baraya Extended Care addresses critical gaps in long-term care, supporting Saudi Arabia's Vision 2030 healthcare goals. DUBAI, UAE and RIYADH, Saudi Arabia, July 15, 2025 -- TVM Capital Healthcare announces the closing of a Series B fundraising, surpassing its target and bringing the total capital raised to USD 124 million for Baraya Extended Care ["Baraya"], a leading provider of long-term care and rehabilitation services in Saudi Arabia. This fundraise comes at a critical moment, as Saudi Arabia faces a
HONG KONG and MACAU, July 15, 2025 -- The eight exceptional young explorers of the 2025 YF Life Jr. Space Camp Program are ready for their unforgettable nine-day space exploration journey in United States! These Jr. astronauts were selected after a series of intense competition by an esteemed panel of seven influential figures from various fields, including Ms. Candy Chea Shuk-mui, Ten Outstanding Young Persons Awardee and Media Veteran; Prof. Chan Chi Hou, Vice-President (Community Engagement) at City University of Hong Kong; Ir. Dr. Raymond Ho Chung-tai, Hong Kong Deputy to the 10th and 11
SUZHOU, China, July 15, 2025 -- Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through its advanced AI and molecular dynamics(MD) platform. This powerful platform recently supported the successful design of BGM1812, a novel dual AMY3R/CTR receptor agonist for obesity treatment, as published in the July 2025 issue of the Journal of Medicinal Chemistry. This achievement underscores Divamics' consistent ability to empower its partners in accelerating their drug discovery pipelines. AI-Powered Efficiency & Pre
- The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of ultra-long-acting subcutaneously administered ASC47 (half-life up to 40 days) in combination with four doses of semaglutide (0.5 mg, once weekly) in 28 participants with obesity. - Initiated in May 2025, all 28 participants were enrolled in less than two months. - Topline data are expected in the fourth quarter of 2025. HONG KONG, July 15, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis&
SYDNEY, July 15, 2025 -- Miroma Project Factory (MPF), a leader in digital innovation for health and wellbeing, is proud to announce the expanded commercial release of StandingTall, the revolutionary home-based balance training program developed in collaboration with Professor Kim Delbaere, showcasing her life's work in falls prevention. StandingTall is a clinically validated, easy-to-use, and engaging exercise app designed to improve balance, boost confidence, and prevent falls among older adults. Now positioned for widespread adoption, StandingTall offers a proven, scalable s
BEIJING, July 15, 2025 -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma. Choroidal malignant melanoma is a common
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brands Anticipate approximately $345 million in annualized EBITDA synergies by 2
Earnings Call Scheduled for 9:30 p.m. ET on August 3, 2025 MILPITAS, Calif., July 14, 2025 -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it will report its second quarter 2025 unaudited financial results on Sunday, August 3, 2025. Management will hold a conference call at 9:30 p.m. Eastern Time on Sunday, August 3, 2025. Listeners may access the call by dialing: US (Toll Free): +1-888-346-8982